Doliver Advisors LP increased its position in shares of ImmunityBio, Inc. (NASDAQ:IBRX - Free Report) by 110.0% in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 210,000 shares of the compan